SAB Biotherapeutics, Inc. (SABS)
NASDAQ: SABS · IEX Real-Time Price · USD
2.840
-0.010 (-0.35%)
At close: Jul 19, 2024, 4:00 PM
2.880
+0.040 (1.41%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
SAB Biotherapeutics Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for SAB Biotherapeutics stock have an average target of 13, with a low estimate of 6.00 and a high estimate of 25. The average target predicts an increase of 357.75% from the current stock price of 2.84.
Analyst Consensus: Strong Buy
* Price targets were last updated on Jun 7, 2024.
Analyst Ratings
The average analyst rating for SABS stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 3 | 3 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Brookline Capital | Brookline Capital | Strong Buy Initiates $8 | Strong Buy | Initiates | $8 | +181.69% | Jun 7, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $6 | Strong Buy | Reiterates | $6 | +111.27% | May 21, 2024 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $25 | Strong Buy | Maintains | $25 | +780.28% | May 21, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $6 | Strong Buy | Reiterates | $6 | +111.27% | Apr 16, 2024 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $25 | Strong Buy | Maintains | $25 | +780.28% | Apr 16, 2024 |
Financial Forecast
Revenue This Year
963.90K
from 2.24M
Decreased by -56.95%
Revenue Next Year
n/a
from 963.90K
EPS This Year
-4.16
from -7.64
EPS Next Year
-3.18
from -4.16
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 992,250 | n/a | n/a | n/a | n/a |
| Avg | 963,900 | n/a | n/a | n/a | n/a |
| Low | 926,100 | n/a | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -55.7% | - | - | - | - |
| Avg | -56.9% | - | - | - | - |
| Low | -58.6% | - | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | -4.08 | -1.12 | -1.14 |
| Avg | -4.16 | -3.18 | -3.39 |
| Low | -4.18 | -5.06 | -5.45 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.